Cargando...
Alternative scheduling of pulsatile, high dose sunitinib efficiently suppresses tumor growth
BACKGROUND: Increased exposure to multitargeted kinase inhibitor sunitinib is associated with improved outcome, emphasizing the importance of maintaining adequate dosing and drug levels. The currently approved schedule (50 mg daily, four weeks on, two weeks off) precludes further dose-intensificatio...
Gardado en:
| Publicado en: | J Exp Clin Cancer Res |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
BioMed Central
2016
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5013589/ https://ncbi.nlm.nih.gov/pubmed/27604186 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13046-016-0411-2 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|